ArticleInternational journal of clinical pharmacy2024

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.

Wenwang Lang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.